Recent Updates
Recently added Catalysts

Cethrin

Phase 1

Spinal Cord Injury | Small molecule | Neurology |Vertex Pharmaceuticals Incorporated|Last Updated: Apr 14, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials1
Total Enrollment48

FDA Designations

No designations recorded

Clinical trial landscape

Cethrin · 1 trial · 1 indication

Phase 1 1
NCT00500812A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord InjuriesSpinal Cord Injury
COMPLETED48 Analytics
PHASE1COMPLETED
A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries
Spinal Cord Injury
NCT0050081248
Unlock trial analytics

Study Endpoints

Primary Endpoints

The primary goal of this study is to determine the safety and tolerability of Cethrin when administered in conjunction with fibrin sealant to the dura mater of the spinal cord.
Prestudy, 24-72 hrs, 6 weeks, 3, 6 & 12 months

Secondary Endpoints

Efficacy by AIS
Pre-study, 24-72 hrs, 6 weeks, 3, 6 & 12 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
0.3 mgEXPERIMENTALSubjects Receiving 0.3 mg Cethrin
1 mgEXPERIMENTALSubjects receiving 1 mg Cethrin
3 mgEXPERIMENTALSubjects receiving 3 mg Cethrin
6 mgEXPERIMENTALSubjects receiving 6 mg Cethrin
9 mgEXPERIMENTALSubjects receiving 9 mg Cethrin

Interventions

NameTypeDescription
CethrinDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range16 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: Patients will be enrolled in this study only if they meet all of the following criteria: * Informed Consent Form signed by the patient or patient's legal representative. * Male or female, aged 16-70 years, inclusive. * For Group 1, patients with acute thoracic (T2-T12) spinal c...

Countries:United StatesCanada
Unlock Eligibility Criteria

Frequently asked questions about Cethrin

What is Cethrin used for in Spinal Cord Injury?

Cethrin is an investigational small molecule being developed for the treatment of acute thoracic and cervical spinal cord injuries. It is designed to address the neurological damage associated with these injuries, though it is not yet approved and remains in clinical development.

What does Cethrin target?

Cethrin is a small molecule that targets the Rho signaling pathway, which is involved in the inhibition of nerve regeneration after spinal cord injury. By modulating this pathway, Cethrin aims to promote recovery of neurological function following acute spinal cord trauma.

Who makes Cethrin?

Cethrin is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker VRTX. The company is conducting clinical research to evaluate the safety and efficacy of Cethrin for spinal cord injury.

What phase is Cethrin in?

Cethrin is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and tolerability in patients with acute spinal cord injuries.

What clinical trials is Cethrin in?

Cethrin has been studied in one completed Phase 1 clinical trial, identified as NCT00500812. This trial, titled "A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries," enrolled 48 participants in the United States and Canada.

Is Cethrin the same as BA-210?

Yes, Cethrin is also known as BA-210. In clinical trial records, the drug is referred to as Cethrin (BA-210), confirming that both names refer to the same investigational compound being studied for spinal cord injury.